Similar articles

• Bladder cancer: natural history, tumor markers, and early detection strategies.

  Foresman WH, Messing EM. Foresman WH, et al. Semin Surg Oncol. 1997 Sep-Oct;13(5):299-306. doi: 10.1002/(sici)1098-2388(199709/10)13:5<299::aid-ssu3>3.0.co;2-8. Semin Surg Oncol. 1997. PMID: 9259085 Review.
• Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder.

  Grossfeld GD, Muscheck M, Stein JP, Chew K, Cote RJ, Ginsberg DA, Waldman FM, Carroll PR. Grossfeld GD, et al. Adv Exp Med Biol. 1999;462:425-35. doi: 10.1007/978-1-4615-4737-2_33. Adv Exp Med Biol. 1999. PMID: 10599445 Review. No abstract available.
• [Prognostic factors in urothelial carcinoma].

  Vögeli TA, Ackermann R. Vögeli TA, et al. Urologe A. 2001 Nov;40(6):442-6. doi: 10.1007/s001200170002. Urologe A. 2001. PMID: 11760346 Review. German.
• Molecular prognostic factors in bladder cancer.

  Schalken JA. Schalken JA. Eur Urol. 1998;33 Suppl 4:13-4. doi: 10.1159/000052254. Eur Urol. 1998. PMID: 9615200 Review. No abstract available.
• Immunotherapy: The development of immunotherapy in urothelial bladder cancer.

  Powles T. Powles T. Nat Rev Clin Oncol. 2015 Apr;12(4):193-4. doi: 10.1038/nrclinonc.2015.51. Epub 2015 Mar 17. Nat Rev Clin Oncol. 2015. PMID: 25781573 No abstract available.